达比加群在儿童血栓栓塞性疾病的应用研究进展
Research of dabigatran in children with thromboembolic diseases
周姝含 1胡长平 1罗平2
作者信息
- 1. 中南大学湘雅药学院药理学系,长沙 410078
- 2. 中南大学湘雅医院药学部,长沙 410008
- 折叠
摘要
近年来,静脉血栓栓塞症在儿童人群中发病率逐渐升高.达比加群作为新型直接口服抗凝血药,具有剂量固定、口服方便、无需监测国际标准化比值(INR)、与食物和药物的相互作用少、起效快以及血浆半衰期短等优点,现已成为预防和治疗儿童血栓栓塞性疾病的重要药物.达比加群酯口服颗粒于2021年6月经FDA批准用于治疗3个月至12岁的儿童静脉血栓以及复发性血栓,同时批准达比加群酯口服胶囊剂用于治疗8岁及以上患者的静脉血栓,以及预防完成首次静脉血栓治疗后的血栓复发.本文就达比加群在防治儿童血栓栓塞性疾病的研究进展进行综述.
Abstract
In recent years,the incidence of venous thromboembolism in children is gradually increasing.As a new type of direct oral anticoagulant,dabigatran has the advantages of fixed dose,convenient oral administration,no need to monitor international standardized ratio,few interactions with food and drugs,fast onset,and short plasma half-life.Dabigatran has therefore become an important drug for the prevention and treatment of thromboembolism in children.Dabigatran etexilate oral granules were approved by the FDA in June 2021 for venous thrombosis and recurrent thrombosis in children aged 3 months to 12 years old.At the same time,dabigatran etexilate oral capsules were approved for the treatment of venous thrombosis in children aged 8 years and above,as well as for preventing the recurrence of thrombosis after the first venous thrombosis treatment.This article reviewed the research progress of dabigatran in the prevention and treatment of thromboembolic diseases in children.
关键词
达比加群/达比加群酯/直接口服抗凝血药/儿童/血栓栓塞Key words
dabigatran/dabigatran etexilate/direct oral anticoagulant/child/thromboembolism引用本文复制引用
基金项目
国家自然科学基金资助项目(No.82173817)
国家自然科学基金资助项目(No.82241025)
长沙市自然科学基金(No.kq2208366)
临床用药卫生技术评估专项课题(No.2023WSJSPGZXKT-24号)
出版年
2024
NETL
NSTL
万方数据